Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

• Histologically confirmed malignant solid tumor
• Advanced disease, meeting both of the following criteria: Metastatic or unresectable disease and standard curative or palliative measures do not exist or are no longer effective.
• No known active brain metastases
• Life expectancy > 3 months
• ECOG performance status 0-2
• Bilirubin normal
• No uncontrolled intercurrent illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or social situation that would limit study compliance.
• Negative pregnancy test
• Fertile patients must use effective contraception
• Recovered from prior therapy
• No prior chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C).
• No prior targeted therapy within the past 4 weeks
• No prior immunotherapy within the past 4 weeks
• No prior radiotherapy within the past 4 weeks.
• No more than 2 prior chemotherapy regimens for advanced solid tumors.
• No other concurrent investigational agents. Bisphosphonate therapy (e.g., pamidronate or zolendronate) is not considered investigational therapy.
• No concurrent antiretroviral therapy for HIV-positive patients.
• No other concurrent anticancer agents or therapies.
• Tumor has spread to other parts of the body or cannot be removed by surgery.
• More than 4 weeks since chemotherapy, biological therapy, or radiation therapy.
• No more than two previous chemotherapy regimens for advanced solid tumor.
• WBC >= 3,000/mm^3
• Platelet count >= 100,000/mm^3
• Creatinine clearance >= 60 mL/min
• Absolute neutrophil count >= 1,500/mm³
• AST and ALT =< 2.5 times upper limit of normal
• No prior cumulative cisplatin dose > 300 mg/m^2
• No preexisting neuropathy <= grade 2
• Not pregnant or nursing